Related Experiment Video
Updated: Aug 14, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
Parents' dilemma: A therapeutic decision for children with spinal muscular atrophy (SMA) type 1
Sophie Boursange1,2,3, Marco Araneda4, Caroline Stalens5
1Université Paris Cité, Laboratoire de Psychologie Clinique, Psychopathologie, Psychanalyse, Boulogne-Billancourt, France.
Insights
Parents of children with SMA type 1 faced difficult decisions regarding innovative therapies. While most felt involved, non-hesitant parents experienced more depression and anxiety, highlighting the complex psychological impact of these life-saving treatments.
Area of Science:
- Pediatric Neurology
- Genetics
- Psychology
Background:
- Spinal Muscular Atrophy (SMA) type 1 is a severe, life-limiting neurodegenerative disorder.
- Innovative therapies offer increased life expectancy for children with SMA type 1.
- Understanding parental experiences with treatment decisions is crucial.
Purpose of the Study:
- To explore parents' experiences with deciding on innovative therapies for SMA type 1.
- To assess the medium-term psychological effects on parents.
- To compare experiences between hesitant and non-hesitant parents, and those receiving gene therapy versus other innovative treatments.
Main Methods:
- In-depth interviews, self-administered questionnaires, and validated psychological scales (BDI-II, STAI-Y, PSI-SF, SOC-13, PBA, DAS 16, FICD).
- Comparison between parents who hesitated versus those who did not.
- Comparison between parents whose children received gene therapy (GT) versus other innovative therapies.
Main Results:
- Most parents felt involved in decision-making and satisfied with treatment outcomes.
- Non-hesitant parents reported higher depression (p<0.001), anxiety (p=0.022), and parental stress (p=0.026) than hesitant parents.
- Parents receiving GT reported higher depression (p=0.036) than those receiving other therapies.
- Qualitative data revealed a strong desire to save the child's life, fear of end-of-life care, trust in physicians, and hope for the child's future.
Conclusions:
- Hesitation before treatment decisions did not predict higher depression or anxiety.
- Parents faced significant dilemmas in urgent situations, with ongoing reflection throughout the care process.
- The decision-making process for innovative SMA therapies is complex and emotionally taxing for parents.
Background:
SMA type 1 is a severe neurodegenerative disorder that, in the absence of curative treatment, leads to death before 1 year of age without ventilatory support. Three innovative therapies are available to increase life expectancy.
Purpose:
(i) To increase knowledge about parents' experiences with their decision to have opted for an innovative therapy; (ii) to assess the middle-term psychological consequences in the parents' lives.
Methods:
We used an in-depth interview; a self-administrated questionnaire and self-report scales (BDI-II, STAI-Y, PSI-SF, SOC-13, PBA, DAS 16 and FICD). We compared parents hesitant before the decision to parents who were not-hesitant and the group of parents whose child was treated with gene therapy (GT) to parents whose child received another innovative therapy.
Main Results:
We included n = 18 parents of 13 children. Parent's mean age was 34.7 (±5.2), child's average age was 44.3 months (±38.0). Retrospectively, most parents felt involved by doctors in decision-making on treatment, they felt their point of view was considered and were satisfied with the effects of the treatment. The group of parents "non-hesitant" was more depressed (p < 0.001), more anxious (p = 0.022) and had higher parental stress (p = 0.026) than the group of "hesitant" parents; the group of "GT-treated" parents was more depressed (p = 0.036) than the group of parents with "other therapy". Qualitative data highlights revealed: the need to save the child's life at all costs; the fear of coping with end of life and palliative care, the high value of perceived physician confidence in the treatment, the hope that the child will acquire autonomy or be cured. At the time of the decision, no parents felt they fully understood all of the issues regarding therapy and the disease.
Conclusion:
Hesitating before making a decision did not predispose parents to depression and anxiety. The narratives suggest that the parents faced a dilemma regarding their child's health in an urgent context. The decision was not final, and parents will continue to think about it throughout the care process.
More Related Videos
05:55Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
Published on: October 3, 2011
09:18Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
Related Concept Videos
Skeletal Muscle Relaxants: Therapeutic Uses
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Satellite Stem Cells and Muscular Dystrophy
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Cystic Fibrosis: Management
Sinus disease and chronic...